Novartis gains worldwide rights to elinogrel, a Phase II anti-clotting compound
- Details
- Category: Novartis
Novartis has gained the exclusive worldwide rights to elinogrel, a promising anti-clotting agent in Phase II clinical trials that has shown potential to offer clinical improvements over current anti-clotting medications in helping patients avoid heart attacks and strokes.
Bayer Schering Pharma to invest 100 million Euro in China to build a global R&D center
- Details
- Category: Bayer
Bayer Schering Pharma AG, the pharmaceutical division of Bayer HealthCare (BHC), announced today that it will be strengthening its global Research and Development (R&D) capabilities through the foundation of a global R&D center in Beijing, China. The company will invest some 100 million Euro over the next five years to establish the center.
HemCon Announces Further Successful Results from Live Nail Infection Anti-Fungal Study
- Details
- Category: Product
HemCon Medical Technologies, Inc. has announced results from an independent study investigating the time required to successfully treat fungal infected human nails which is a leading cause of Onychomycosis. The studies were conducted as part of HemCon's continued program of development for a formulation based on its newest proprietary platform technology.
Prasugrel Receives Unanimous Approval Recommendation from FDA Advisory Committee
- Details
- Category: Eli Lilly and Company
The U.S. Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee voted 9 to 0 that prasugrel, an investigational antiplatelet agent, should be approved for the treatment of patients with acute coronary syndromes (ACS) managed with an artery-opening procedure known as percutaneous coronary intervention (PCI), Daiichi Sankyo Company, Limited, (TSE: 4568), and Eli Lilly and Company (NYSE: LLY) announced.
Pfizer to Disclose Payments to US Physicians, Healthcare Professionals and Clinical Investigators
- Details
- Category: Pfizer
Pfizer Inc announced its plans to make publicly available its compensation of U.S. healthcare professionals for consulting, speaking engagements and clinical trials. The disclosure will include payments made to practicing U.S. physicians and other healthcare providers, as well as principal investigators, major academic institutions and research sites for clinical research.
GlaxoSmithKline and Idenix Pharmaceuticals sign worldwide license agreement for IDX899
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline and Idenix Pharmaceuticals, Inc. announced the execution of a license agreement granting GSK exclusive worldwide rights to IDX899. IDX899 is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) in Phase II clinical development being developed by Idenix for the treatment of HIV/AIDS. New NNRTIs are needed to address the increasing prevalence of viral resistance and side effects associated with this drug class.
Lundbeck to acquire US-based Ovation Pharmaceuticals, Inc.
- Details
- Category: Lundbeck
H. Lundbeck A/S (Lundbeck) and Ovation Pharmaceuticals, Inc. (Ovation) today announced that they have entered into a definitive transaction agreement under which Lundbeck, through the wholly owned subsidiary Lundbeck, Inc., will acquire Ovation in an all cash transaction valuing Ovation at up to USD 900 million or approximately DKK 5.2 billion.
More Pharma News ...
- Pfizer and The Pfizer Foundation Recognize "World Cancer Day"
- European Commission (EC) has granted marketing authorisation for Nplate(R) (romiplostim)
- European Commission Clears Acquisition of Zentiva NV by sanofi-aventis
- Strong operating results for Roche in 2008
- Roche Announces Interim Results from a Phase III ATLAS Study
- Lipitor Significantly Reduced hsCRP Levels in Patients with Stable Coronary Artery Disease
- Novartis increases dividend by 25% based on strong 2008 results